Ivermectin cream improves health-related quality of life in patients with rosacea: data from a randomized trial

Br J Dermatol. 2016 Dec;175(6):1366-1368. doi: 10.1111/bjd.14665. Epub 2016 Sep 19.

Authors

A Taieb¹, T Passeron², T Ruzicka³, J Berth-Jones⁴, J Jacovella⁵, M Y Huang⁶, A Wertheimer⁶

Affiliations

¹ Service de Dermatologie et Dermatologie Pédiatrique, Hôpital Saint-André, Bordeaux, France.
² Service de Dermatologie, Hôpital Archet 2, Nice, France.
³ Department of Dermatology and Allergy, Ludwig-Maximilian Universität, Munich, Germany.
⁴ Department of Dermatology, University Hospital, Coventry, U.K.
⁵ Galderma R&D, Sophia Antipolis, France.
⁶ School of Pharmacy, Temple University, Philadelphia, PA, 19140, U.S.A.

PMID: 27061926
DOI: 10.1111/bjd.14665

No abstract available

Publication types

Comparative Study
Letter
Multicenter Study
Randomized Controlled Trial

MeSH terms

Adolescent
Adult
Aged
Dermatologic Agents / administration & dosage*
Humans
Ivermectin / administration & dosage*
Metronidazole / administration & dosage
Middle Aged
Ointments
Quality of Life
Rosacea / drug therapy*
Treatment Outcome
Young Adult

Substances

Dermatologic Agents
Ointments
Metronidazole
Ivermectin